Abstract
We examined the use of antibiotics among 2728 women with a first diagnosis of breast cancer during 1994–2003, and 27 280 population controls in North Jutland County, Denmark, based on hospital discharge diagnoses, prescription use from 1989 to 2002, and population registry data. We found no increased relative risk of breast cancer associated with use compared with nonuse. The odds ratio for breast cancer associated with more than 10 prescriptions for antibiotics was 1.00 (95% CI 0.86 –1.15). Relative risks were similar for different classes of antibiotics. A subanalysis based on cases and controls younger than 70 years of age, with data on first birth and number of children, showed similar risk estimates even after adjustment for age at first birth and parity. In our study, use of antibiotics was not associated with an increased risk of breast cancer.
Similar content being viewed by others
Main
Breast cancer is the most commonly occurring cancer in women, but we have only limited knowledge about nonhormonal risk factors for this malignancy (Hankinson and Hunter, 2002). Recent case–control (Velicer et al, 2004) and cohort (Knekt et al, 2000) studies have suggested that use of antibiotics may increase the risk of breast cancer (Knekt et al, 2000; Velicer et al, 2004). A mechanism for any causal association is unknown, but it has been hypothesised that antibiotics may affect the ability of intestinal microflora to metabolise phytochemicals from edible plants into compounds that may protect against cancer (Setchell et al, 1981; Velicer et al, 2003). Since antibiotics are commonly used and breast cancer is common, any increased risk has major public health potential.
To further evaluate this association, we conducted a population-based case–control study of breast cancer in Denmark, a country with one of the highest incidences of breast cancer worldwide (National Board of Health, 2003).
Methods
The National Health Service in each Danish county provides health care for all residents, with free access to general practitioners and hospitals, and also refunding a variable proportion of the costs of prescribed drugs. All services are registered by use of the unique 10-digit civil registry number that is assigned to all Danish citizens shortly after birth. Its use allows valid linkage between population-based registries and the creation of a complete hospital discharge and prescription history for each individual.
Cases with breast cancer
The Hospital Discharge Registry of North Jutland County retains key information on all patients discharged from nonpsychiatric hospitals in the county since 1977 (Andersen et al, 1999; Dalton et al, 2003; Floyd et al, 2003). Registry files include information on the civil registry number of the patient, dates of admission and discharge, and up to 20 discharge diagnoses (Andersen et al, 1999). Diagnoses are assigned exclusively by the doctor of record according to the Danish version of the International Classification of Diseases, 8th revision, and the 10th revision thereafter (Andersen et al, 1999).
All patients with an incident diagnosis of breast cancer (ICD8: 174.00, 174.01, 174.02, 174.08, 174.09 and ICD10: C50.0–C50.6, C50.8, C50.9) were identified in the period 1 January, 1994–31 March, 2003 (n=2728) using the Hospital Discharge Registry.
Selection of controls
Controls were identified in the Civil Registration System, which has had electronic records on all changes in vital status, including change of address, date of emigration, and date of death for the entire Danish population since 1968 and 10 controls were randomly selected for each case, matched by year of birth and county of residence. A total of 10 controls were selected using incidence density sampling, that is, the controls were residents in North Jutland County, alive and at risk for a first hospital admission for breast cancer at the time the corresponding case was diagnosed, but could be subsequently diagnosed as a case. A total of 27 280 controls were included in the study.
Data sources
The population-based Pharmaco-Epidemiological Prescription Database of North Jutland, established in 1989, was used to identify all prescriptions filled for antibiotics between 1989 and 2002 (Dalton et al, 2003; Floyd et al, 2003; Sørensen et al, 2004). The county is served by pharmacies equipped with computerised accounting systems through which data are sent to the Danish National Health Service and to the Prescription Database, with key information about prescriptions for refundable drugs. Thus, the database includes information on each patient's civil registry number, the type of drug prescribed according to the Anatomical Therapeutical Chemical classification system (ATC), and the date the prescription was filled. We identified all prescriptions for antibiotics (ATC codes: Penicillins: J01C, Cephalosporins: J01D A01, J01D A03, J01D A06, J01D A10, J01D A11, J01D A13, J01D A24, Macrolides: J01F, Tetracyclines: J01A, Quinolones: J01 M; Sulphonamides: J01E B02, J01E E01) among cases and controls redeemed before the date of hospitalisation of cases. These drugs are available in Denmark only by prescription. Before 1996, prescriptions to children were marked with a special code and issued to the parents, but afterwards were issued in the child's civil registry number; all prescriptions to children were excluded from the analysis. Reimbursement for tetracyclines was withdrawn in 1997. Prescriptions for postmenopausal hormone replacement therapy were also identified in the database (ATC codes: G03C, G03D, G03F, G03 H B01) and categorised as 0, 1–5, 6+prescriptions. Age at first birth and number of children were available only for women below 70 years, ascertained through linkage to the Danish Civil Registration System.
Statistical methods
We used conditional logistic regression to estimate odds ratios (OR)s and associated 95% confidence intervals (CIs) for breast cancer according to the number of prescriptions of antibiotics and different types of antibiotics, adjusted for postmenopausal hormone replacement therapy in the overall analysis. We adjusted for age at first birth, parity, and use of postmenopausal hormone replacement therapy in cases (n=1917) and controls (n=19 170) less than 70 years of age. Wald tests were used to test for homogeneity.
Results
Table 1 provides summary data for the 2728 cases and 27 280 controls. The mean age was 62 years for both cases and controls.
Table 1 gives the ORs for breast cancer according to number of antibiotic prescriptions. Almost all risk estimates were close to 1.0. The ORs for breast cancer associated with more than 10 prescriptions for antibiotics was 1.00 (95% CI 0.86–1.15). There were no substantial differences in findings for various classes of antibiotics (penicillins, cephalosporins, macrolides, tetracyclines, quinolones, and sulphonamides) (Table 2 ). In women less than 70 years of age, the adjusted OR for breast cancer was 1.11 (95% CI 0.93–1.32) for women with more than 10 prescriptions.
Relative risks did not vary substantially between parous and nulliparous women (data not shown).
Discussion
In this large population-based case–control study, we found no increased risk of breast cancer in association with antibiotic use. Our study thus does not confirm findings from the Seattle case–control study of 2266 women with breast cancer and 7953 controls (Velicer et al, 2004). In that investigation, the relative risk was 1.56–2.66 for more than 10 prescriptions, but the effect was also seen in the category of 1–10 prescriptions with an OR of 1.49 (95% CI 1.28 –1.79) (Velicer et al, 2004). In a subanalysis, an increased risk of fatal breast cancer was seen for all antibiotic classes (Velicer et al, 2004). In a Finnish cohort study of women younger than 50 years of age, self-reported antibiotic use for urinary tract infections was associated with a breast cancer relative risk of 1.74 (95% CI 1.13 –2.68) (Knekt et al, 2000).
Several issues are relevant to the interpretation of our data. The main strengths of this study are its large size, the population-based design based on the Danish health-care system, and the use of exposure data collected before hospitalisation for breast cancer. These data sources have been extensively used in previous pharmacoepidemiological studies (Pedersen et al, 1999; Sørensen et al, 2000; Nielsen et al, 2001; Dalton et al, 2003; Floyd et al, 2003; Sørensen et al, 2004). A limitation is the shorter latency period of maximum 15 years relative to the Seattle study in which the maximum period of exposure to antibiotics was 25 years (Velicer et al, 2004). Also, we had no information for certain breast cancer risk factors such as alcohol consumption. However, confounding factors would have to be related to antibiotic prescriptions and inversely related to breast cancer risk, conditionally adjusted for age, which is an unlikely combination. No restrictions were imposed concerning the length of time cases or controls should have lived in North Jutland County. We obtained prescription data on cases for a mean number of days of 3478 (median: 3508) and, for controls, 3468 (median: 3502), or approximately 9.5 years.
In conclusion, the present data showed no increased breast cancer risk among antibiotic users in a population characterised by one of the highest breast cancer incidence rates worldwide (National Board of Health, 2003), although further study would be useful.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH (1999) The Danish National Hospital Register. Dan Med Bull 46: 263–268
Dalton SO, Johansen C, Mellemkjær L, Nørgård B, Sørensen HT, Olsen JH (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding – population-based cohort study. Arch Intern Med 163: 59–64
Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sørensen HT (2003) Risk of acute pancreatitis in users of azathioprine: a population-based case–control study. Am J Gastroenterol 98: 1305–1308
Hankinson S, Hunter D (2002) Breast cancer. In Textbook of Cancer Epidemiology Adami H-O, Hunter D, Trihopoulos D (eds) pp 301–339. Oxford: Oxford University Press
Knekt P, Adlercreutz H, Rissanen H, Aromaa A, Teppo L, Heliovaara M (2000) Does antibacterial treatment for urinary tract infection contribute to the risk of breast cancer. Br J Cancer 82: 1107–1110
National Board of Health (2003) Cancer Incidence in Denmark 1999. Copenhagen: National Board of Health, Health Statistics
Nielsen GL, Sørensen HT, Larsen H, Pedersen L (2001) Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case control study. BMJ 322: 266–270
Pedersen G, Schønheyder HC, Steffensen FH, Sørensen HT (1999) Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J Antimicrob Chemother 43: 119–126
Setchell KD, Lawson AM, Boriello SP, Harkness R, Gordon H, Morgan DM, Kirk DN, Adlercreatz H, Anderson LC, Axelson M (1981) Lignan formation in man – microbial involvement and possible roles in relation to cancer. Lancet 2: 4–7
Sørensen HT, Mellemkjær L, Nielsen GL, Baron JA, Olsen JH, Karagas MR (2004) Skin cancers and non-Hodgkin's lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 96: 709–711
Sørensen HT, Olsen JH, Mellemkjær L, Thulstrup AM, Steffensen FH, McLaughlin JK, Baron JA (2000) Cancer risk and mortality in users of calcium channel blockers: a cohort study. Cancer 89: 165–170
Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH (2004) Antibiotic use in relation to the risk of breast cancer. JAMA 291: 827–835
Velicer CM, Lampe JW, Heckbert SR, Potter JD, Taplin SH (2003) Hypothesis: is antibiotic use associated with breast cancer? Cancer Causes Control 14: 739–747
Acknowledgements
The study obtained support from the Western Danish Research Forum for Health Sciences and Leo and Ingeborg Dannin Foundation for Scientific Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sørensen, H., Skriver, M., Friis, S. et al. Use of antibiotics and risk of breast cancer: a population-based case–control study. Br J Cancer 92, 594–596 (2005). https://doi.org/10.1038/sj.bjc.6602313
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6602313
Keywords
This article is cited by
-
The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer
Cancer and Metastasis Reviews (2021)
-
Gut microbiome, body weight, and mammographic breast density in healthy postmenopausal women
Cancer Causes & Control (2021)
-
Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study
BMC Surgery (2010)
-
Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study
Breast Cancer Research (2008)
-
Association between Antibiotic use Prior to Breast Cancer Diagnosis and Breast Tumour Characteristics (United States)
Cancer Causes & Control (2006)